BOSTON , June 30, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing

BOSTON, June 25, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing

Boston, Mass. – May 11, 2020 – Akouos, a precision genetic medicine company developing gene therapies to potentially restore, improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 23rd American Society of Gene and Cell Therapy

Akouos Closes $105 Million Series B Financing Appoints Vicki Sato, Ph.D., and Heather Preston, M.D., to Board of Directors Boston, Mass. – March 3, 2020   –  Akouos, Inc. (“Akouos”), a precision genetic medicine company developing potential gene therapies to restore, improve or preserve hearing,

Boston, Mass. – January 24, 2020  –  Akouos , a precision genetic medicine company developing gene therapies to potentially improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 43rd Annual Midwinter Meeting of the Association

Boston, Mass. – January 9, 2020  – Akouos, a precision genetic medicine company developing potential gene therapies to restore and preserve hearing, today announced two key senior leadership appointments. Morgan Molloy joins the team as chief corporate development officer, and Karoline Shair,